This proposal is an application for renewal of the collaborative University of Washington (UW)/Puget Sound Blood Center K12 program to train Scholars in clinical research in benign hematology and transfusion medicine. We will build on our long tradition of excellence in research and clinical care in these disciplines to address the critical shortage of clinician scientists investigating clinical problems in benign hematology and transfusion medicine. The program is led by three highly experienced and successful mentors and researchers and includes a large multidisciplinary group of potential mentors from all areas of benign hematology and transfusion medicine and other disciplines, including biostatistics and clinical outcomes research. Our structured program includes training in clinical hematology and transfusion medicine, research methodologies, scientific writing and presentation, and individualized research projects. The training in research methodologies will be provided in close collaboration with the UW Institute for Translational Health Sciences KL2 Multidisciplinary Clinical Research Career Development Program. Key to our proposed program is a strong mentoring plan, beginning with the entry of the scholars into the program and continuing after the scholars leave the program for the next phase of their careers. A structured scholar recruitment and program evaluation plan is described. Our current K12 program has been successful in training scholars in benign hematology and transfusion medicine - a tradition we plan to continue and strengthen with the current application.

Public Health Relevance

This is an application for renewal of a training program to increase he number of physician scientists studying important clinical issues in benign hematology and transfusion medicine. The program includes comprehensive training and mentoring to produce successful investigators in these areas.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (F1))
Program Officer
Werner, Ellen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Vande Vusse, Lisa K; Madtes, David K; Guthrie, Katherine A et al. (2014) The association between red blood cell and platelet transfusion and subsequently developing idiopathic pneumonia syndrome after hematopoietic stem cell transplantation. Transfusion 54:1071-80
Gyurkocza, Boglarka; Gutman, Jonathan; Nemecek, Eneida R et al. (2014) Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant 20:549-55
Kuderer, Nicole M; Wolff, Antonio C (2014) Enhancing therapeutic decision making when options abound: toxicities matter. J Clin Oncol 32:1990-3
Kuderer, Nicole M; Lyman, Gary H (2014) Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res 133 Suppl 2:S122-7
Hobbs, William E; Moore, Emily E; Penkala, Rebecca A et al. (2013) Cocaine and specific cocaine metabolites induce von Willebrand factor release from endothelial cells in a tissue-specific manner. Arterioscler Thromb Vasc Biol 33:1230-7
Byon, John C H; Chen, Jing; Doty, Raymond T et al. (2013) FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function. Blood 122:2903-10
Wong, Trisha E; Huang, Yuan-Shung; Weiser, Jason et al. (2013) Antithrombin concentrate use in children: a multicenter cohort study. J Pediatr 163:1329-34.e1
Byon, John C H; Papayannopoulou, Thalia (2012) MicroRNAs: Allies or foes in erythropoiesis? J Cell Physiol 227:7-13
de Claro, R Angelo; Zhu, Xiaodong; Tang, Jingjing et al. (2011) Hematopoietic Fas deficiency does not affect experimental atherosclerotic lesion formation despite inducing a proatherogenic state. Am J Pathol 178:2931-7